890 related articles for article (PubMed ID: 32028068)
21. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
Bochem J; Zelba H; Spreuer J; Amaral T; Wagner NB; Gaissler A; Pop OT; Thiel K; Yurttas C; Soffel D; Forchhammer S; Sinnberg T; Niessner H; Meier F; Terheyden P; Königsrainer A; Garbe C; Flatz L; Pawelec G; Eigentler TK; Löffler MW; Weide B; Wistuba-Hamprecht K
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933966
[TBL] [Abstract][Full Text] [Related]
22. Gene expression and immune infiltration in melanoma patients with different mutation burden.
Wang L; Chen F; Liu R; Shi L; Zhao G; Yan Z
BMC Cancer; 2021 Apr; 21(1):379. PubMed ID: 33836680
[TBL] [Abstract][Full Text] [Related]
23. PMEL as a Prognostic Biomarker and Negatively Associated With Immune Infiltration in Skin Cutaneous Melanoma (SKCM).
Zhang S; Chen K; Liu H; Jing C; Zhang X; Qu C; Yu S
J Immunother; 2021 Jul-Aug 01; 44(6):214-223. PubMed ID: 34028390
[TBL] [Abstract][Full Text] [Related]
24. HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.
Huang FX; Wu JW; Cheng XQ; Wang JH; Wen XZ; Li JJ; Zhang Q; Jiang H; Ding QY; Zhu XF; Zhang XS; Ding Y; Li DD
Front Immunol; 2022; 13():902167. PubMed ID: 36003385
[TBL] [Abstract][Full Text] [Related]
25. Development and Validation of a CD8+ T Cell Infiltration-Related Signature for Melanoma Patients.
Yuan Y; Zhu Z; Lan Y; Duan S; Zhu Z; Zhang X; Li G; Qu H; Feng Y; Cai H; Song Z
Front Immunol; 2021; 12():659444. PubMed ID: 34040608
[TBL] [Abstract][Full Text] [Related]
26. Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma.
Liu D; Yang X; Wu X
Front Immunol; 2021; 12():663495. PubMed ID: 34025664
[TBL] [Abstract][Full Text] [Related]
27. CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab).
Fietz S; Zarbl R; Niebel D; Posch C; Brossart P; Gielen GH; Strieth S; Pietsch T; Kristiansen G; Bootz F; Landsberg J; Dietrich D
Cancer Immunol Immunother; 2021 Jun; 70(6):1781-1788. PubMed ID: 33196890
[TBL] [Abstract][Full Text] [Related]
28. LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers.
Pan JH; Zhou H; Cooper L; Huang JL; Zhu SB; Zhao XX; Ding H; Pan YL; Rong L
Front Immunol; 2019; 10():6. PubMed ID: 30761122
[No Abstract] [Full Text] [Related]
29. Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy.
Emran AA; Chatterjee A; Rodger EJ; Tiffen JC; Gallagher SJ; Eccles MR; Hersey P
Trends Immunol; 2019 Apr; 40(4):328-344. PubMed ID: 30853334
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological, immune and molecular correlates of
Lingohr P; Dohmen J; Semaan A; Branchi V; Dietrich J; Bootz F; Kalff JC; Matthaei H; Dietrich D
Epigenomics; 2019 May; 11(6):639-653. PubMed ID: 30821175
[No Abstract] [Full Text] [Related]
31. Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma.
Long Q; Huang C; Huang J; Meng Q; Cheng Y; Li Y; He L; Chen M; Zhang C; Wang X; Zhu W; Peng J; Shi D; Zheng F; Dong P; Deng W
J Adv Res; 2022 Sep; 40():153-166. PubMed ID: 36100323
[TBL] [Abstract][Full Text] [Related]
32. Can CpG methylation serve as surrogate markers for immune infiltration in cancer?
Bacolod MD; Barany F; Fisher PB
Adv Cancer Res; 2019; 143():351-384. PubMed ID: 31202362
[TBL] [Abstract][Full Text] [Related]
33. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
34. Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.
Vilgelm AE; Johnson CA; Prasad N; Yang J; Chen SC; Ayers GD; Pawlikowski JS; Raman D; Sosman JA; Kelley M; Ecsedy JA; Shyr Y; Levy SE; Richmond A
J Natl Cancer Inst; 2016 Jun; 108(6):djv406. PubMed ID: 26719346
[TBL] [Abstract][Full Text] [Related]
35. Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.
van der Westhuizen A; Lyle M; Graves MC; Zhu X; Wong JWH; Cornall K; Ren S; Pugliese L; Levy R; Majid A; Vilain RE; Bowden NA
Cancer Res Commun; 2022 Aug; 2(8):814-826. PubMed ID: 36923309
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival.
Micevic G; Thakral D; McGeary M; Bosenberg MW
Pigment Cell Melanoma Res; 2019 May; 32(3):435-440. PubMed ID: 30343532
[TBL] [Abstract][Full Text] [Related]
37. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
38. Genome-wide DNA methylation profile analysis identifies an individualized predictive signature for melanoma immune response.
Yan J; Wu X; Zhu Y; Cang S
J Cancer Res Clin Oncol; 2023 Jan; 149(1):343-356. PubMed ID: 36595044
[TBL] [Abstract][Full Text] [Related]
39. Characterization of m
Zhu M; Cui Y; Mo Q; Zhang J; Zhao T; Xu Y; Wu Z; Sun D; Zhang X; Li Y; You Q
Front Immunol; 2021; 12():782551. PubMed ID: 34975871
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of the TNF-α receptors, TNFRSF2 and TNFRSF9, on cell migration molecules Fascin-1 and Versican in acute leukemia.
El Kramani N; Elsherbiny NM; El-Gayar AM; Ebrahim MA; Al-Gayyar MMH
Cytokine; 2018 Nov; 111():523-529. PubMed ID: 29861382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]